Phosphatidylinositol-3-kinase as a therapeutic target in melanoma

Clinical Cancer Research

Volumn 15, Issue 9, 2009, Pages 3029-3036

  Aziz, Saadia A ^a   Davies, Michael ^c   Pick, Elah ^a   Zito, Christopher ^a   Jilaveanu, Lucia ^a   Camp, Robert L ^b   Rimm, David L ^b   Kluger, Yuval ^d   Kluger, Harriet M ^a  

^a YALE CANCER CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; B RAF KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P110; PROTEIN P85;

ARTICLE; CONTROLLED STUDY; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MELANOMA; ONCOGENE N RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BRAIN NEOPLASMS; CELL PROLIFERATION; CHROMONES; ENZYME INHIBITORS; HUMANS; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; MELANOMA; MORPHOLINES; NEVUS, PIGMENTED; PHOSPHORYLATION; PROTEIN ARRAY ANALYSIS; SKIN NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR CELLS, CULTURED;

EID: 65649126397     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2768     Document Type: Article

References (36)

1. Rigel DS. Malignant melanoma: incidence issues and their effect on diagnosis and treatment in the 1990s. Mayo Clin Proc 1997;72:367-371 (Pubitemid 28194205)
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
3. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004;351:998-1012. (Pubitemid 39166263)
4. Dillon RL, White DE, Muller WJ. The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene 2007;26:1338-1345 (Pubitemid 46328463)
5. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006;7:606-619 (Pubitemid 44100518)
6. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 2001;17:615-675 (Pubitemid 33096187)
7. Zhao JJ, Cheng H, Jia S, et al. The p110α isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation. Proc Natl Acad Sci U S A 2006;103:16296-16300
8. Manning BD, Cantley LC. United at last: The tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling. Biochem Soc Trans 2003;31:573-578
9. Hanada M, Feng J, Hemmings BA. Structure, regulation and function of PKB/AKT-a major therapeutic target. Biochim Biophys Acta 2004;1697:3-16. (Pubitemid 38326757)
10. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002;14:381-395 (Pubitemid 34214843)
11. Granville CA, Memmott RM, Gills JJ, Dennis PA. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin Cancer Res 2006;12:679-689 (Pubitemid 43259846)
12. Krasilnikov M, Adler V, Fuchs SY, et al. Contribution of phosphatidylinositol 3-kinase to radiation resistance in human melanoma cells. Mol Carcinog 1999; 24:64-69
13. Smalley KS, Herlyn M. Targeting intracellular signaling pathways as a novel strategy in melanoma therapeutics. Ann N Y Acad Sci 2005;1059:16-25. (Pubitemid 43211606)
14. Govindarajan B, Sligh JE,Vincent BJ, et al. Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J Clin Invest 2007;117: 719-729
15. Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 2006;5:1136-1144 (Pubitemid 43881305)
16. Meier F, Busch S, Lasithiotakis K, et al. Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. Br J Dermatol 2007;156:1204-1213
17. Bedogni B, Welford SM, Kwan AC, Ranger-Moore J, Saboda K, Powell MB. Inhibition of phosphatidylinositol- 3-kinase and mitogen-activated protein kinase kinase 1/2 prevents melanoma development and promotes melanoma regression in the transgenic TPRas mouse model. Mol Cancer Ther 2006;5:3071-3077 (Pubitemid 46092048)
18. Hayakawa M, Kaizawa H, Moritomo H, et al. Synthesis and biological evaluation of 4-morpholino- 2-phenylquinazolines and related derivatives as novel PI3 kinase p110α inhibitors. Bioorg Med Chem 2006; 14:6847-6858 (Pubitemid 44307656)
19. Yaguchi S, Fukui Y, Koshimizu I, et al. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J Natl Cancer Inst 2006;98: 545-556
20. Singh RS, Diwan AH, Zhang PS, Prieto VG. Phosphoinositide 3-kinase is not overexpressed in melanocytic lesions. JCutan Pathol 2007;34:220-225 (Pubitemid 46239310)
21. Dhawan P, Singh AB, Ellis DL, Richmond A. Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-κB and tumor progression. Cancer Res 2002;62:7335-7342 (Pubitemid 36025257)
22. Dai DL, Martinka M, Li G. Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J Clin Oncol 2005; 23:1473-1482 (Pubitemid 46260035)
23. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002;8: 1323-1327 (Pubitemid 35373567)
24. McCarthy MM, DiVito KA, Sznol M, et al. Expression of tumor necrosis factor-related apoptosis-inducing ligand receptors 1 and 2 in melanoma. Clin Cancer Res 2006;12:3856-3863
25. Divito KA, Berger AJ, Camp RL, Dolled-Filhart M, Rimm DL, Kluger HM. Automated quantitative analysis of tissue microarrays reveals an association between high Bcl-2 expression and improved outcome in melanoma. Cancer Res 2004;64:8773-8777 (Pubitemid 39552096)
26. Berger AJ, Kluger HM, Li N, et al. Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. Cancer Res 2003; 63:8103-8107
27. Kluger HM, Kluger Y, Gilmore-Hebert M, et al. cDNA microarray analysis of invasive and tumorigenic phenotypes in a breast cancer model. Lab Invest 2004; 84:320-331 (Pubitemid 41656487)
28. Kluger HM, McCarthy MM, Alvero AB, et al. The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization. J Transl Med 2007;5:6.
29. Rimm DL, Camp RL, Charette LA, Costa J, Olsen DA, Reiss M. Tissue microarray: a new technology for amplification of tissue resources. Cancer J 2001;7: 24-31. (Pubitemid 32199100)
30. Hennessy BT, Lu Y, Poradosu E, et al. Pharmacodynamic markers of perifosine efficacy. Clin Cancer Res 2007;13:7421-7431
31. Noh WC, Mondesire WH, Peng J, et al. Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 2004;10:1013-1023
32. Thor AD, Liu S, Edgerton S, et al. Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. J Clin Oncol 2000;18:3230-3239
33. Schwertschlag U, Chiorean, EG, Anthony, CJ, et al. Phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of SF1126 a vascular targeted pan phosphoinositide 3-kinase (PI3K) inhibitor in patients with solid tumors. In: Proceeding in American Society of Clinical Oncology. Orlando (FL): 2008.
34. Folkes AJ, Ahmadi K, Alderton WK, et al. The identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonylpiperazin- 1-ylmethyl)-4-morpholin-4-yl- thieno[3,2- d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable Inhibitor of class IPI3 kinase for the treatmentof cancer. J Med Chem 2008;51:5522-5532
35. Maira SM, Stauffer F, Brueggen J, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008;7: 1851-1863.
36. Papadopoulos K, Markman, B, Tabernero, et al. A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a novel PI3K inhibitor, XL765, administered orally to patients (pts) with advanced solid tumors. In: Proceedings in American Society of Clinical Oncology. Orlando (FL): 2008.